EDAP — Edap Tms S.a.

EDAP TMS Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenue: USD 16.1 million, a record for Q3 and a 6% increase year-over-year.
• HIFU Revenue: USD 7.7 million, up 57% from Q3 2024, driven by 8 Focal One placements (6 capital sales, 2 operating leases).
• Gross Profit: EUR 6 million (USD 6.96 million), a year-over-year increase from EUR 5.2 million; gross margin improved to 43% from 39.4%.
• Operating Loss: EUR 4.9 million, an improvement from EUR 5.8 million in Q3 2024.
• Net Loss: EUR 5 million (EUR 0.13 per share), improved from EUR 6.4 million (EUR 0.17 per share) in the same period last year.
• Cash and Cash Equivalents: EUR 10.6 million, down from EUR 16.3 million in the prior quarter.
• Inventory: Decreased to EUR 13.8 million from EUR 15.5 million, reflecting just-in-time inventory management.

2. Strategic Updates and Business Highlights

• Continued focus on making Focal One the standard of care for localized prostate cancer, with notable placements in top academic centers.
• Growth in U.S. Focal One procedures increased by over 15% year-over-year.
• Positive reimbursement trends, particularly among Medicare Advantage providers, enhancing patient access and hospital economics.
• Significant clinical validation for HIFU therapy, with a peer-reviewed study showing favorable long-term outcomes compared to traditional radiation therapy.
• Progress in expanding clinical applications, including a new BPH clinical study in the U.S. and ongoing commercialization efforts for endometriosis treatment.

3. Forward Guidance and Outlook

• Maintained 2025 revenue guidance: core HIFU business expected to grow by 26% to 34%, while noncore ESWL and distribution revenue projected to decline by 25% to 30%.
• Confidence in achieving year-end targets with Q4 revenue expected to align with annual guidance of USD 58 million to USD 62 million.

4. Bad News, Challenges, or Points of Concern

• Continued decline in noncore distribution and ESWL businesses, which fell by 16% year-over-year.
• Anticipated tariff impact of approximately EUR 900,000 for the year, which could affect profitability.
• Cash reserves decreased significantly, raising concerns about financial flexibility for ongoing investments.

5. Notable Q&A Insights

• The proceeds from the European Investment Bank (EIB) credit facility will be used for product development, clinical development, and commercial growth, primarily focused on the HIFU core business.
• The company is optimistic about the growth of U.S. Focal One procedures, with a mix of Medicare and commercial payer coverage contributing to this increase.
• Management reiterated confidence in Q4 performance, aligning with their annual revenue guidance despite typical seasonal softness in Q3.

This summary encapsulates the key financial metrics, strategic initiatives, outlook, challenges, and insights from the Q&A session, providing a comprehensive overview of EDAP TMS's performance and future direction.